IL139512A0 - Oral medicinal preparations with reproducible release of the active ingredient gatifloaxacin or its pharmaceutically suitable salts or hydrates - Google Patents

Oral medicinal preparations with reproducible release of the active ingredient gatifloaxacin or its pharmaceutically suitable salts or hydrates

Info

Publication number
IL139512A0
IL139512A0 IL13951299A IL13951299A IL139512A0 IL 139512 A0 IL139512 A0 IL 139512A0 IL 13951299 A IL13951299 A IL 13951299A IL 13951299 A IL13951299 A IL 13951299A IL 139512 A0 IL139512 A0 IL 139512A0
Authority
IL
Israel
Prior art keywords
gatifloaxacin
hydrates
active ingredient
suitable salts
pharmaceutically suitable
Prior art date
Application number
IL13951299A
Other languages
English (en)
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of IL139512A0 publication Critical patent/IL139512A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13951299A 1998-05-09 1999-04-29 Oral medicinal preparations with reproducible release of the active ingredient gatifloaxacin or its pharmaceutically suitable salts or hydrates IL139512A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19820801A DE19820801A1 (de) 1998-05-09 1998-05-09 Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
PCT/EP1999/002893 WO1999058129A1 (de) 1998-05-09 1999-04-29 Orale arzneiformen mit reproduzierbarer wirkstofffreisetzung von gatifloxacin oder pharmazeutisch verwendbaren salzen oder hydraten

Publications (1)

Publication Number Publication Date
IL139512A0 true IL139512A0 (en) 2001-11-25

Family

ID=7867223

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13951299A IL139512A0 (en) 1998-05-09 1999-04-29 Oral medicinal preparations with reproducible release of the active ingredient gatifloaxacin or its pharmaceutically suitable salts or hydrates

Country Status (28)

Country Link
US (1) US6291462B1 (pt)
EP (1) EP1077703B1 (pt)
JP (1) JP2002514600A (pt)
KR (1) KR100587210B1 (pt)
CN (1) CN1198615C (pt)
AR (1) AR019279A1 (pt)
AT (1) ATE235242T1 (pt)
AU (1) AU753482B2 (pt)
BR (1) BR9910350A (pt)
CA (1) CA2325636A1 (pt)
CO (1) CO5050341A1 (pt)
DE (2) DE19820801A1 (pt)
DK (1) DK1077703T3 (pt)
ES (1) ES2195573T3 (pt)
HK (1) HK1033281A1 (pt)
HU (1) HUP0101597A3 (pt)
IL (1) IL139512A0 (pt)
MY (1) MY118569A (pt)
NO (1) NO20005385D0 (pt)
NZ (1) NZ507968A (pt)
PE (1) PE20000480A1 (pt)
PL (1) PL343936A1 (pt)
PT (1) PT1077703E (pt)
RU (1) RU2226394C2 (pt)
SK (1) SK16772000A3 (pt)
UA (1) UA60364C2 (pt)
WO (1) WO1999058129A1 (pt)
ZA (1) ZA200006440B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302015B6 (cs) 1999-10-08 2010-09-08 Affinium Pharmaceuticals, Inc. Inhibitory Fab I
US6413969B1 (en) * 2000-09-13 2002-07-02 Bristol-Myers Squibb Company Gatifloxacin pentahydrate
ATE420640T1 (de) * 2001-04-06 2009-01-15 Affinium Pharm Inc Fab-i-inhibitoren
US6589955B2 (en) * 2001-06-20 2003-07-08 Bristol-Myers Squibb Company Pediatric formulation of gatifloxacin
DK1575951T3 (da) * 2002-12-06 2014-09-15 Debiopharm Int Sa Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
EP1608377B1 (en) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US20050031683A1 (en) * 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
WO2005021000A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Solid oral dosage forms of gatifloxacin
MY144477A (en) * 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
SI1828167T1 (sl) * 2004-06-04 2014-12-31 Debiopharm International Sa Forum "Apres-Demain" Akrilamidni derivati kot anitibiotična sredstva
US20060247255A1 (en) * 2005-05-02 2006-11-02 Patel Satishkumar A Method for preparing a stable gatifloxacin composition
CA2617230A1 (en) * 2005-08-02 2007-02-08 Baxter International Inc. Medical products and parenteral formulations
WO2007067416A2 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
CN100415212C (zh) * 2006-07-21 2008-09-03 哈药集团制药总厂 一种含乳酸卡德沙星的口服制剂
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
MX356695B (es) 2012-06-19 2018-06-11 Debiopharm Int Sa Profarmacos derivados de (e)-n-metil-n-((3-metilbenzofuran-2-il)me til)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il) acrilamida.
KR20180114177A (ko) 2016-02-26 2018-10-17 데비오팜 인터네셔날 에스 에이 당뇨병성 족부 감염의 치료제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH089597B2 (ja) 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
EP0522128B1 (en) * 1991-01-30 1996-01-17 The Wellcome Foundation Limited Water-dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
US5436253A (en) * 1993-09-08 1995-07-25 Daiichi Pharmaceutical Co., Ltd. Pyridonecarboxylic acid derivatives and mycotic infections
US5858411A (en) * 1994-12-19 1999-01-12 Daiichi Pharmaceutical Co., Ltd. Sustained-release granular preparations and production process thereof
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug

Also Published As

Publication number Publication date
MY118569A (en) 2004-12-31
US6291462B1 (en) 2001-09-18
PT1077703E (pt) 2003-08-29
NO20005385L (no) 2000-10-26
PL343936A1 (en) 2001-09-10
NO20005385D0 (no) 2000-10-26
ATE235242T1 (de) 2003-04-15
HK1033281A1 (en) 2001-08-24
PE20000480A1 (es) 2000-05-20
ES2195573T3 (es) 2003-12-01
EP1077703A1 (de) 2001-02-28
JP2002514600A (ja) 2002-05-21
KR20010043408A (ko) 2001-05-25
KR100587210B1 (ko) 2006-06-08
HUP0101597A3 (en) 2003-01-28
BR9910350A (pt) 2001-09-25
NZ507968A (en) 2002-12-20
UA60364C2 (uk) 2003-10-15
HUP0101597A2 (hu) 2001-11-28
SK16772000A3 (sk) 2001-05-10
WO1999058129A1 (de) 1999-11-18
CN1198615C (zh) 2005-04-27
AU4035299A (en) 1999-11-29
CN1300216A (zh) 2001-06-20
DE19820801A1 (de) 1999-11-25
AR019279A1 (es) 2002-02-13
EP1077703B1 (de) 2003-03-26
AU753482B2 (en) 2002-10-17
CO5050341A1 (es) 2001-06-27
CA2325636A1 (en) 1999-11-18
DE59904737D1 (de) 2003-04-30
RU2226394C2 (ru) 2004-04-10
ZA200006440B (en) 2002-02-08
DK1077703T3 (da) 2003-06-23

Similar Documents

Publication Publication Date Title
IL139512A0 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloaxacin or its pharmaceutically suitable salts or hydrates
HUP0900587A3 (en) Stable salts of 3,3-diphenylpropylamines and preparation thereof
EG23875A (en) Oral pharmaceutical pulsed release dosage form
HRPK20040323B3 (en) Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
IL137445A0 (en) Pharmaceutically active compounds and methods of use thereof
IL136827A0 (en) Oral pharmaceutical extended release dosage form
HUP0101461A3 (en) Novel pyridazine derivatives and drugs containing the same as the active ingredient
HK1030543A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP1115396A4 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS, AND METHODS OF USE THEREOF
HUP0102369A3 (en) Amino acid derivatives and drugs containing the same as the active ingredient
ZA991982B (en) Salts of keto acids and amine derivatives and their use for the preparation of medicaments.
HUP0002719A3 (en) Controlled release pharmaceutical preparation with ace inhibitor as active agent
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
HUP0201667A2 (en) Oral form of administration
EE04095B1 (et) Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks
HUP0104238A2 (en) Benzoxazole derivatives and drugs containing the same as the active ingredient and their use
AU1053501A (en) Polyazanaphthalene compound and medicinal use thereof
AUPP672198A0 (en) Pyrazolopyridine compound and pharmaceutical use thereof
AUPQ462299A0 (en) Pyrazolopyridine compound and pharmaceutical use thereof
SI1077703T1 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
AU2572800A (en) Morphan derivatives or salts thereof and medicinal compositions containing the same
HUP0001697A3 (en) Benzopyranopyrrole and benzopyranopyridine derivatives, pharmaceutical compositions thereof, preparation and use of the compounds
CZ20011327A3 (cs) Farmaceutická kompozice s trvalým uvolňováním farmaceuticky účinného činidla
SI1043976T1 (sl) Oralna farmacevtska dozirna oblika s podaljsanim sproscanjem